Researchers have identified the synaptic protein EPAC2 as a potential therapeutic target for fragile X syndrome (FXS), according to a preclinical study published in Genetic Engineering News. Blocking EPAC2 in an FXS mouse model restored abnormal patterns of brain activity and improved several FXS-associated behavioral symptoms.
The study focused on EPAC2, a protein involved in synaptic signaling. In the FXS mouse model, its inhibition normalized neural activity that is typically disrupted in the disorder. The findings suggest a novel mechanism for addressing the underlying neurobiology of FXS, which currently lacks effective treatments.
As a preclinical investigation, this work is at an early stage. The next step would involve validating the target in additional animal studies before any potential human trials could be considered. No timeline for clinical development has been disclosed.
Fragile X syndrome is the most common inherited cause of intellectual disability and autism spectrum disorders. Current management focuses on behavioral and educational interventions, creating significant unmet need for targeted pharmacological therapies.
The research team emphasized the need for further studies to confirm EPAC2's role and to develop selective inhibitors suitable for clinical use. The identification of this target opens a new avenue for drug discovery in FXS.